Acrivastine

Acrivastine

Acrivastine
Systematic (IUPAC) name
(E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid
Clinical data
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • US: B (No risk in non-human studies)
Legal status
Routes of
administration
oral
Pharmacokinetic data
Biological half-life 1.5 hours
Excretion Renal
Identifiers
CAS Registry Number  N
ATC code R06
PubChem CID:
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  N
ChEMBL  Y
Chemical data
Formula C22H24N2O2
Molecular mass 348.438 g/mol
 N   

Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking Histamine H1 receptors.

This non-sedating antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories. It should not be confused with Benadryl Once a Day which has cetirizine as the active ingredient and is also sold by McNeil in the UK. It is available as an over-the-counter medicine in the UK, and is available with or without pseudoephedrine under the Benadryl brand.

In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D also contains the decongestant pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.[1]

Comparisons with other popular antihistamines

Unlike cetirizine or loratadine, for which the standard dose is one tablet per day, a single acrivastine tablet may be taken up to three times a day.[2] Not to be taken by over 65s, pregnant women, or people with compromised liver or kidney function.

References

  1. ^ SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule U.S. National Library of Medicine, National Institutes of Health, May 2008
  2. ^ "Benadryl Allergy Relief". electronic Medicines Compendium (eMC). 2014. Retrieved 4 July 2014.